Literature DB >> 21989155

Phylogenetic groups and cephalosporin resistance genes of Escherichia coli from diseased food-producing animals in Japan.

Tetsuo Asai1, Kaori Masani, Chizuru Sato, Mototaka Hiki, Masaru Usui, Kotaro Baba, Manao Ozawa, Kazuki Harada, Hiroshi Aoki, Takuo Sawada.   

Abstract

A total of 318 Escherichia coli isolates obtained from different food-producing animals affected with colibacillosis between 2001 and 2006 were subjected to phylogenetic analysis: 72 bovine isolates, 89 poultry isolates and 157 porcine isolates. Overall, the phylogenetic group A was predominant in isolates from cattle (36/72, 50%) and pigs (101/157, 64.3%) whereas groups A (44/89, 49.4%) and D (40/89, 44.9%) were predominant in isolates from poultry. In addition, group B2 was not found among diseased food-producing animals except for a poultry isolate. Thus, the phylogenetic group distribution of E. coli from diseased animals was different by animal species. Among the 318 isolates, cefazolin resistance (minimum inhibitory concentrations: ≥32 μg/ml) was found in six bovine isolates, 29 poultry isolates and three porcine isolates. Of them, 11 isolates (nine from poultry and two from cattle) produced extended spectrum β-lactamase (ESBL). The two bovine isolates produced bla(CTX-M-2), while the nine poultry isolates produced bla(CTX-M-25) (4), bla(SHV-2) (3), bla(CTX-M-15) (1) and bla(CTX-M-2) (1). Thus, our results showed that several types of ESBL were identified and three types of β-lactamase (SHV-2, CTX-M-25 and CTX-M-15) were observed for the first time in E. coli from diseased animals in Japan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989155      PMCID: PMC3206820          DOI: 10.1186/1751-0147-53-52

Source DB:  PubMed          Journal:  Acta Vet Scand        ISSN: 0044-605X            Impact factor:   1.695


Findings

Pathogenic Escherichia coli is the causative agent of colibacillosis that brings severe clinical sighs such as diarrhea, meningitis and sepsis in domestic animals. E. coli can be divided into four phylogenetic groups using multiplex PCR method [1]. Several authors have analyzed the distribution of the main phylogenetic groups among E. coli strains isolated from human and animals. Extraintestinal pathogenic E. coli usually belongs to groups B2 and D, while the commensal strains are groups A and B1 in humans [2]. In healthy food-producing animals, a predominant distribution of group B1 was reported in E. coli from cattle, while group A was predominantly prevalent in pigs and chickens [3-5]. On the contrary, although predominant phylogenetic groups were reported in E. coli from diseased poultry [6-8], little information regarding to diseased cattle and pigs was available. Antimicrobial agents have been widely used for treatment of colibacillosis in domestic animals. Antimicrobial resistance is more frequently found in E. coli isolates from diseased animals than apparently healthy animals [9]. Increases in cephalosporin-resistant E. coli in domestic animals have been a significant worldwide concern including Japan. Extended-spectrum β-lactamase (ESBL)-producing isolates of E. coli were identified in domestic animals around 2000 in Japan [10,11]. The third and greater generation cephalosporin antibiotics are clinically important antimicrobial agents in human and animal medicines. Such agents are approved to treat bacterial diseases in cattle and pigs and not licensed for enhancing animal growth in Japan. However, cephalosporin-resistant E. coli has been identified in isolates from not only cattle and pigs but also poultry in Japan [10,12]. At present the reason for the prevalence of cephalosporin-resistant E. coli in poultry is unclear. In the present study, we determined the distribution of phylogenetic groups in E. coli from food-producing animals affected with colibacillosis in Japan. In addition, we examined the characteristics of cephalosporin-resistant isolates of E. coli from the diseased animals. A total of 318 E. coli isolates from different animals affected with colibacillosis between 2001 and 2006 throughout Japan were used in this study: 72 bovine isolates, 89 poultry isolates and 157 porcine isolates in 23, 20 and 28 prefectures, respectively, located from north to south Japan. All the strains were stored in 10% skimmed milk at -80°C until use. The phylogenetic grouping was performed by multiplex PCR as described by Clermont et al. [1]. The minimum inhibitory concentration (MIC) of cefazolin (CEZ) was determined by an agar dilution method in accordance with the guidelines of the Clinical Laboratory Standards Institute (CLSI) [13,14]. The MIC of some of the isolates to CEZ was previously determined [15]. Susceptibilities of CEZ-resistant isolates to several β-lactamase antibiotics, cefpodoxime, cefotaxime, ceftazidime, aztreonam, imipenem and meropenem were tested according to the CLSI guideline [13,14] using the commercially available broth microdilution test (Eiken Co. LTD, Tokyo, Japan). E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality controls for MIC determination. The Chi-square test was performed on the antimicrobial susceptibility and the phylogenetic subgroup data. The resistance rates in each phylogenetic group were compared with those in the overall strains tested. For each comparison, a P value of < 0.05 was considered to denote significant differences. A double-disk synergy test for detection of ESBLs was performed using clavulanate and cefotaxime, ceftazidime, cefpodoxime, or aztreonam disks (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) as previously described [10]. Detection of β-lactamase genes was carried out by PCR using primers for bla, blaand blaas described previously [10]. Multiplex PCR was applied to the AmpC genes, groups ACC, FOX, MOX, CIT and EBC, detection as previously described [16]. As for samples positive for CIT group, sequence analysis was performed using the primer pairs for amplification of the full-length gene of bla[10]. Multiplex PCR was used for blaCTX-M detection as previously described [17]. Subtypes of CTX-M β-lactamases were determined using the primer pairs as follows: CTX-MF (5'-GACTATTCATGTTGTTGTTATTTC-3') and CTX-MR (5'-TTACAAACCGTTGGTGACG-3') for CTX-M-group1 [18]; blaF (5'-ATGATGACTCAGAGCATTCG-3') and blaR (5'-TCAGAAACCGTGGGTTACGA-3') for CTX-M-group2 [10]; CTXM825F (5'-CGCTTTGCCATGTGCAGCACC-3') [19] and CTXM20 (5'-ATAACCGTCGGTGACAATT-3') [17] for CTX-M-group8 and 25/26. Nucleotide sequences were preformed directly on both strands of PCR products by using dye terminator chemistry. The DNA alignments and deduced amino acid sequences were examined using the BLAST program (National Center for Biotechnology Information, USA). The phylogenetic analysis revealed that 318 isolates of E. coli from diseased animals were classified into four phylogenetic groups (Table 1). The phylogenetic group A was commonly predominant in isolates from cattle (36/72, 50%) and pigs (101/157, 64.3%) whereas groups A (44/89, 49.4%) and D (40/89, 44.9%) were predominant in isolates from poultry. The B2 group was rarely found in E. coli from healthy cattle, chickens and pigs in Brazil [3] as well as Japan. In Korea, group B2 was also not found in E. coli isolates from food-producing animals [4]. These trends were similar to those of the present study although clinical isolates from food-producing animals were used here. On the other hand, in the United States, groups A and D were predominant (38% and 28%, respectively) in E. coli from diseased poultry and group B2 was also found in 19% [6]. In European countries, group B2 was often isolated from diseased poultry [7,8]. Thus, the distribution of phylogenetic groups may be determined not only by the animal species but also by their health status or geographical region.
Table 1

Distribution of Escherichia coli isolate phylogenetic groups from diseased animals in Japan between 2001 and 2006

Phylogenetic groupNo. of isolates testedNo. of isolates resistant to cefazolin (%)


CattlePoultrySwineTotalCattlePoultrySwineTotal
A36441011813 (8.3)21 (47.7)2 (2.0)26 (14.4)
B11849312 (11.1)1 (25.0)0 (0)3 (9.7)
B201010 (NA)0 (0)0 (NA*)0 (0)
D1840471051 (5.6)7 (17.5)1 (2.1)9 (8.6)

Total72891573186 (8.3)29 (32.6)3 (1.9)38 (11.9)

* NA: not applicable

Distribution of Escherichia coli isolate phylogenetic groups from diseased animals in Japan between 2001 and 2006 * NA: not applicable Previous studies showed that the phylogenetic group distribution may be related to antimicrobial resistance prevalence in human isolates of E. coli [20]. In the present study, 38 (11.9%) isolates exhibited CEZ resistance (MIC: ≥32 μg/ml) (Table 2). Twenty-six (68.4%) of the CEZ-resistant isolates belonged to group A. However, rates of CEZ resistance among the phylogenetic groups, except for group B2, were in 8.6-14.4%. Thus, no significant difference in the resistance rates between the phylogenetic groups was observed.
Table 2

MICs of β-lactam antibiotics for 38 cefazolin-resistant isolates of E. coli from diseased animals isolated between 2002 and 2006

MICs (μg/ml) of:

Animal speciesβ-lactamasenYear isolatedPhylogenetic groupCefazolinCefpodoximeCefotaximeCeftazidimeAztreonamImipenemMeropenem
(32)*(8)(64)(32)(32)(16)(16)
CattleCTX-M-212003 (1)A (1)256>32>32416≤1≤4
CTX-M-2/TEM-112003 (1)B1 (1)256>32>328>16≤1≤4
CMY-212003 (1)A (1)2568≤1≤1≤4≤1≤4
CMY-2/TEM-112002 (1)D (1)256>32816≤4≤1≤4
TEM-112003 (1)A (1)328≤12≤4≤1≤4
ND12002 (1)B1 (1)12816≤18≤4≤1≤4

PoultryCTX-M-212006A (1)>512>32>322≤4≤1≤4
CTX-M-15/TEM-112006A (1)>512>32>32328≤1≤4
CTX-M-2542005(3), 2006 (1)A (2), D (2)>512>3216->322-4≤4-8≤1≤4
SHV-232004 (3)A (3)256-51232->328-324-16≤4-8≤1≤4
CMY-2102004(1), 2006 (10)A (5), B1 (1), D (5)512->512>324-328-32≤4-8≤1≤4
TEM-172004 (2), 2005 (5)A (7)64->51216-32≤1-24-8≤4≤1≤4
ND22002 (1), 2005 (1)A (2)128-25616-32≤1-24≤4≤1≤4

SwineCMY-2/TEM-112004 (1)A (1)>512>32163216≤1≤4
ND22002 (1), 2003 (1)A (1), D (1)128-2564-8≤1≤1≤4≤1≤4

* Resistance breakpoint (μg/ml) defined by CLSI guideline.

MICs of β-lactam antibiotics for 38 cefazolin-resistant isolates of E. coli from diseased animals isolated between 2002 and 2006 * Resistance breakpoint (μg/ml) defined by CLSI guideline. Of the 38 resistant isolates, 11 isolates from two cattle and nine poultry produced ESBLs while the remaining 27 isolates produced AmpC β-lactamase. The two bovine isolates expressed bla, while, of the nine poultry, four expressed bla, three expressed bla, one expressed blaand one expressed bla. The blagene, being non-ESBL, was detected in 12 isolates. This is the first description of the bla, blaand blaenzymes in E. coli from food-producing animals in Japan. In human patients in Japan, E. coli strains carrying blawere predominantly prevalent around 1997 [21], and then the dominant β-lactamase type has changed to the CTX-M-9 group, including blaand bla, since 2001 [22]. As for food-producing animals, E. coli carrying blahave emerged in apparently healthy broilers [10] and cattle [11] in 2000 and pigs in 2003 [12]. In 2002, bla, identical to amino acid sequence of bla, was identified in cephalosporin-resistant isolates from healthy broilers [10]. On the other hand, of the remaining 27 AmpC β-lactamase producing isolates, 13 isolates were PCR positive for CIT group, being identified bla: 10 from poultry, two from cattle and one from swine (Table 2). There were no positive signals for group ACC, FOX, MOX and EBC. The blagene was found to be prevalent in a wide range of food-producing animal species in Japan [10,12], as well as other countries [23]. In the present study, 5 of 8 isolates producing CTX-M ESBL and all three isolates producing SHV-type ESBL belonged to group A. However, group B2 is predominant in SHV-type ESBL producing E. coli isolates of human origin whereas group D is predominant in CTX-M enzyme-producing isolates [24]. On the contrary, 7 of 13 isolates producing CMY-2 β-lactamase belonged to group A. Group B1 was dominant in CMY enzyme-producing E. coli from retail broiler meats [25]. It is likely that the genotype of E. coli carrying β-lactamase genes may be different between humans and food-producing animals. It is essential to understand the prevalence of resistance to clinically important antimicrobials in bacteria from food-producing animals. The MICs of six β-lactam antibiotics are summarized in Table 2. All CEZ-resistant isolates were susceptible to imipenem and meropenem. All isolates exhibit cefpodoxime resistance (MIC of breakpoint: ≥8 μg/ml) except for one porcine isolate in which β-lactamase expression was not determined. All isolates expressing CTX-M enzymes exhibit cefotaxime resistance (MIC of breakpoint: ≥64 μg/ml) with the exception of one poultry isolate (MIC: 16 μg/ml) harboring bla. Resistance to ceftazidime was found in three poultry and one porcine isolate with bla, and one poultry isolate with bla. Resistance to aztreonam was found in a single bovine isolate with bla. The MICs of antimicrobials tested varied in isolates with each β-lactamase gene. In conclusion, our study suggests that the distribution of phylogenetic groups in E. coli from diseased domestic animals varies regionally in addition to animal species. Moreover, ESBL-producing E. coli from the animals were frequently assigned to a specific group, being different from human ESBL isolates. Further study on ESBL-producing E. coli from several animal sources using the PCR-based phylogenetic typing and the other genotyping methods may clarify the relationship of the resistant bacteria and/or the resistance determinants prevalent in the food-chain and the environments.

Abbreviations

CEZ: cefazoline; CLSI: Clinical and Laboratory Standards Institute; ESBL: extended spectrum β-lactamase; ESC: extended-spectrum cephalosporinase; MICs: Minimum inhibitory concentrations.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TA conceived the study, the study design, interpreted the data and drafted the manuscript. KM carried out large parts of the resistance gene determination. CS helped to carried out resistance gene determination. MH helped to carry out determination of phylogenetic groups. MU helped to carried out resistance gene determination. KB carried out antimicrobial susceptibility testing. MO carried out antimicrobial susceptibility testing. KH carried out antimicrobial susceptibility testing and helped to draft the manuscript. HA helped to carry out the resistance gene determination and draft the manuscript. TS helped to draft the manuscript. All authors read and approved the final manuscript.
  23 in total

1.  Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp.

Authors:  Johann D D Pitout; Ashfaque Hossain; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Rapid and simple detection of blaCTX-M genes by multiplex PCR assay.

Authors:  Li Xu; Vicki Ensor; Savita Gossain; Kathy Nye; Peter Hawkey
Journal:  J Med Microbiol       Date:  2005-12       Impact factor: 2.472

3.  A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan.

Authors:  T Yagi; H Kurokawa; N Shibata; K Shibayama; Y Arakawa
Journal:  FEMS Microbiol Lett       Date:  2000-03-01       Impact factor: 2.742

4.  Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli.

Authors:  J R Johnson; P Delavari; M Kuskowski; A L Stell
Journal:  J Infect Dis       Date:  2000-11-22       Impact factor: 5.226

5.  Extended-spectrum-beta-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002: report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program.

Authors:  Akemi Kojima; Yoshikazu Ishii; Kanako Ishihara; Hidetake Esaki; Tetsuo Asai; Chitose Oda; Yutaka Tamura; Toshio Takahashi; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Antimicrobial susceptibility of pathogenic Escherichia coli isolated from sick cattle and pigs in Japan.

Authors:  Kazuki Harada; Tetsuo Asai; Akemi Kojima; Chitose Oda; Kanako Ishihara; Toshio Takahashi
Journal:  J Vet Med Sci       Date:  2005-10       Impact factor: 1.267

7.  Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK.

Authors:  Hiran Dhanji; Niamh M Murphy; Michel Doumith; Sema Durmus; Susanne Surman Lee; Russell Hope; Neil Woodford; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-10-01       Impact factor: 5.790

8.  Comparison of Escherichia coli isolates implicated in human urinary tract infection and avian colibacillosis.

Authors:  Kylie E Rodriguez-Siek; Catherine W Giddings; Curt Doetkott; Timothy J Johnson; Mohamed K Fakhr; Lisa K Nolan
Journal:  Microbiology       Date:  2005-06       Impact factor: 2.777

9.  Genetic background of Escherichia coli and extended-spectrum beta-lactamase type.

Authors:  Catherine Branger; Oana Zamfir; Sabine Geoffroy; Geneviève Laurans; Guillaume Arlet; Hoang Vu Thien; Stéphanie Gouriou; Bertrand Picard; Erick Denamur
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

10.  Escherichia coli producing CTX-M-2 beta-lactamase in cattle, Japan.

Authors:  Yutaka Shiraki; Naohiro Shibata; Yohei Doi; Yoshichika Arakawa
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

View more
  14 in total

1.  Phylogenetic analysis of Escherichia coli isolated from broilers with colibacillosis based on gyrA gene sequences.

Authors:  Hamid Shamsi; Karim Mardani; Abdolghaffar Ownagh
Journal:  Can J Vet Res       Date:  2017-01       Impact factor: 1.310

2.  Effects of Clostridium butyricum and Enterococcus faecalis on growth performance, intestinal structure, and inflammation in lipopolysaccharide-challenged weaned piglets.

Authors:  Kangli Wang; Guangyong Chen; Guangtian Cao; Yinglei Xu; Yongxia Wang; Caimei Yang
Journal:  J Anim Sci       Date:  2019-10-03       Impact factor: 3.159

Review 3.  Human and avian extraintestinal pathogenic Escherichia coli: infections, zoonotic risks, and antibiotic resistance trends.

Authors:  Melha Mellata
Journal:  Foodborne Pathog Dis       Date:  2013-08-20       Impact factor: 3.171

4.  Detection of aac(6')-Ib-cr in avian pathogenic Escherichia coli isolates in Japan.

Authors:  Michiko Kawanishi; Manao Ozawa; Mototaka Hiki; Hitoshi Abo; Akemi Kojima; Tetsuo Asai
Journal:  J Vet Med Sci       Date:  2013-07-12       Impact factor: 1.267

5.  CTX-M-type extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from cases of bovine mastitis in Japan.

Authors:  Nobukazu Saishu; Hiroichi Ozaki; Toshiyuki Murase
Journal:  J Vet Med Sci       Date:  2014-05-01       Impact factor: 1.267

6.  Phylogenetic grouping, epidemiological typing, analysis of virulence genes, and antimicrobial susceptibility of Escherichia coli isolated from healthy broilers in Japan.

Authors:  Mototaka Hiki; Masaru Usui; Tetsuo Akiyama; Michiko Kawanishi; Mai Tsuyuki; Saiki Imamura; Hideto Sekiguchi; Akemi Kojima; Tetsuo Asai
Journal:  Ir Vet J       Date:  2014-07-10       Impact factor: 2.146

7.  The occurrence of CTX-M-25-producing Enterobacteriaceae in day-old broiler chicks in Japan.

Authors:  Montira Yossapol; Michiyo Sugiyama; Tetsuo Asai
Journal:  J Vet Med Sci       Date:  2017-08-07       Impact factor: 1.267

8.  Yupingfeng polysaccharides enhances growth performance in Qingyuan partridge chicken by up-regulating the mRNA expression of SGLT1, GLUT2 and GLUT5.

Authors:  Fuquan Yin; Ruixia Lan; Zhengmin Wu; Zhijing Wang; Haohao Wu; Zhiming Li; Hui Yu; Zhihui Zhao; Hua Li
Journal:  Vet Med Sci       Date:  2019-04-11

9.  Chronological Change of Resistance to β-Lactams in Salmonella enterica serovar Infantis Isolated from Broilers in Japan.

Authors:  Takehisa Chuma; Daisuke Miyasako; Hesham Dahshan; Tomoko Takayama; Yuko Nakamoto; Francis Shahada; Masato Akiba; Karoku Okamoto
Journal:  Front Microbiol       Date:  2013-05-21       Impact factor: 5.640

10.  Extended-spectrum β-lactamase- and AmpC-producing enterobacteria in healthy broiler chickens, Germany.

Authors:  Felix Reich; Viktoria Atanassova; Günter Klein
Journal:  Emerg Infect Dis       Date:  2013-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.